We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
基础慢性肝脏疾病对接受免疫检查点抑制剂治疗的 肿瘤患者的疗效及安全性的影响.
- Authors
刘 丹; 姚甜甜; 张宇涵; 王贵强; 王 艳
- Abstract
Immune checkpoint inhibitors(ICIs) have recently been approved for the treatment of cancer, and the number of cancer patients with chronic liver disease(CLD) receiving ICIs is growing rapidly. However, whether CLD affects the efficiency and safety of ICIs is becoming a research focus. This review summarizes the efficiency and safety of ICIs in cancer patients with CLD, including chronic viral hepatitis, non-alcoholic fatty liver disease, autoimmune liver disease, and cirrhosis. Specifically, data on hepatitis B virus reactivation of patients with chronic hepatitis B after ICIs treatment were reviewed, which may help to perfect and standardize the guidelines of treatment and following-up for ICIs in CLD patients.
- Publication
Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi, 2022, Vol 38, Issue 11, p2457
- ISSN
1001-5256
- Publication type
Article
- DOI
10.3969/j.issn.1001-5256.2022.11.005